Ikarian Capital, LLC Ventyx Biosciences, Inc. Transaction History
Ikarian Capital, LLC
- $606 Million
- Q4 2024
A detailed history of Ikarian Capital, LLC transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 1,092,590 shares of VTYX stock, worth $1.51 Million. This represents 0.39% of its overall portfolio holdings.
Number of Shares
1,092,590
Previous 192,647
467.15%
Holding current value
$1.51 Million
Previous $419,000
470.88%
% of portfolio
0.39%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding VTYX
# of Institutions
132Shares Held
52.8MCall Options Held
63.4KPut Options Held
78.5K-
Black Rock Inc. New York, NY4.77MShares$6.58 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.48MShares$6.18 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.27MShares$5.9 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY4.05MShares$5.58 Million3.31% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$4.85 Million0.0% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $78M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...